title: Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review.
abstract: To systematically review the efficacy/safety of radiotherapy/temozolomide (TMZ) vs. radiotherapy for treating glioblastoma (GBM), Medline, Current Contents, and Cochrane database were searched. Five studies were reviewed. Median survival ranged from 9.4 to 19.0 months (radiotherapy/TMZ) vs. 7.3-17.1 months (radiotherapy). Survival ranged from 80.2% to 95.0% (radiotherapy/TMZ) vs. 8.3-84.2% (radiotherapy) at 0.5 years and from 20.0% to 61.1% (radiotherapy/TMZ) vs. 5.0-50.6% (radiotherapy) at 1 year. Median progression-free survival (PFS) ranged from 5.5 to 13.0 months (radiotherapy/TMZ) vs. 4.4-7.6 months (radiotherapy). PFS rates at 0.5 years ranged from 53.9-78.0% (radiotherapy/TMZ) vs. 53.9-78.0% (radiotherapy). Radiotherapy/TMZ provides better survival outcomes than radiotherapy alone in treating GBM.
authors: 1Department of Pharmacology, Fujian Medical University, Fuzhou, Fujian, P.R. China.
authors: Li-Juan
authors: LJ
authors: Yang
authors: Chang-Fu
authors: CF
authors: Zhou
authors: Zhi-Xiong
authors: ZX
authors: Lin
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D059248:Chemoradiotherapy; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018572:Disease-Free Survival; D005909:Glioblastoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide